More bullish guidance from the company has Haywood analyst Gianluca Tucci raising his price target on Kits Eyecare ( Kits ...

Following the company’s first quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on ...

As reported by the Globe and Mail, RBC analyst Darko Mihelic March 18 reiterated his “Outperform” rating and 12-month price ...

Its fourth quarter results are in the books and Paradigm Capital analysts J Marvin Wolff remains bullish on Magellan ...

Following the company’s first quarter results, Desjardins analyst Benoit Poirier has trimmed his price target on Transat A.T.

For National Bank analyst Adam Shine it’s not a matter of if, but when. The subject at hand is BCE’s dividend, and when they ...

After a fourth quarter that “exceeded all expectations”, Ventum Capital Markets analyst Rob Goff has raised his price target ...

Following a notable acquisition, RBC analyst Douglas Miehm has raised his price target on Knight Therapeutics.

Its fourth quarter results are in the books and Roth analyst Bill Kirk still thinks there is money to be made on Cresco Labs ...

It’s just getting started. That’s the takeaway from analyst Michael W. Freeman, who initiated coverage of AIDX with a price ...

Following the company’s fourth quarter results, Beacon Securities, Beacon Securities analyst Doug Cooper has cut his price ...

Its fourth quarter results are in the books and Paradigm Capital analyst Daniel Rosenberg thinks there is still a lot of ...